Flexion Therapeutics, Inc. (NASDAQ:FLXN) has earned a consensus recommendation of “Buy” from the eleven research firms that are covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation, seven have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $32.50.

Several equities research analysts have recently issued reports on the company. Northland Securities reaffirmed a “buy” rating and issued a $40.00 price objective on shares of Flexion Therapeutics in a research note on Wednesday. Zacks Investment Research upgraded Flexion Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, August 28th. Needham & Company LLC reissued a “buy” rating and set a $36.00 target price on shares of Flexion Therapeutics in a research report on Sunday, September 17th. ValuEngine raised Flexion Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. Finally, Royal Bank Of Canada set a $44.00 price target on Flexion Therapeutics and gave the company a “buy” rating in a report on Monday, September 11th.

ILLEGAL ACTIVITY WARNING: This report was published by Marea Informative and is the sole property of of Marea Informative. If you are viewing this report on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The original version of this report can be read at http://www.mareainformativa.com/flexion-therapeutics-inc-flxn-receives-average-rating-of-buy-from-brokerages/116022/.

In other Flexion Therapeutics news, insider Yamo Deniz purchased 3,000 shares of the firm’s stock in a transaction that occurred on Friday, September 1st. The stock was purchased at an average cost of $24.15 per share, with a total value of $72,450.00. Following the purchase, the insider now owns 5,000 shares of the company’s stock, valued at $120,750. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last quarter, insiders bought 5,375 shares of company stock worth $131,575. Company insiders own 15.98% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Teachers Advisors LLC increased its stake in Flexion Therapeutics by 21.2% in the 4th quarter. Teachers Advisors LLC now owns 43,468 shares of the specialty pharmaceutical company’s stock worth $827,000 after buying an additional 7,610 shares during the period. Wells Fargo & Company MN lifted its holdings in Flexion Therapeutics by 25.1% during the 1st quarter. Wells Fargo & Company MN now owns 124,717 shares of the specialty pharmaceutical company’s stock valued at $3,356,000 after buying an additional 25,047 shares in the last quarter. Swiss National Bank lifted its holdings in Flexion Therapeutics by 13.2% during the 1st quarter. Swiss National Bank now owns 35,911 shares of the specialty pharmaceutical company’s stock valued at $966,000 after buying an additional 4,200 shares in the last quarter. Ameriprise Financial Inc. bought a new stake in Flexion Therapeutics during the 1st quarter valued at about $1,246,000. Finally, Parametric Portfolio Associates LLC boosted its position in Flexion Therapeutics by 79.0% in the 1st quarter. Parametric Portfolio Associates LLC now owns 27,600 shares of the specialty pharmaceutical company’s stock valued at $743,000 after buying an additional 12,181 shares during the period. Hedge funds and other institutional investors own 83.26% of the company’s stock.

Flexion Therapeutics (FLXN) traded down 1.28% during trading on Wednesday, reaching $26.15. The company had a trading volume of 1,661,246 shares. The firm’s 50 day moving average is $24.20 and its 200 day moving average is $22.44. The company’s market capitalization is $834.32 million. Flexion Therapeutics has a one year low of $15.93 and a one year high of $29.41.

Flexion Therapeutics (NASDAQ:FLXN) last released its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.91) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.80) by ($0.11). On average, equities research analysts predict that Flexion Therapeutics will post ($3.74) earnings per share for the current year.

About Flexion Therapeutics

Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.

Analyst Recommendations for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Stock Ratings for Flexion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc. and related stocks with our FREE daily email newsletter.